Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”

Why Trump's 'Made in America' plan leaves us vulnerable

A generic drug finished in an American factory but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine produced at two independent plants with multiple qualified suppliers. That distinction matters as President Donald Trump moves to bring generic-drug manufacturing back to the United States. He has announced a plan to keep imported generics tariff-free until August 2028, before imposing …

Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”

On July 21, President Donald Trump announced his latest set of sweeping tariffs on the pharmaceutical industry: a 200% levy on imported generic drugs by the year 2029.  This episode is available on Spotify, Apple Podcasts, and Youtube. Trump imposed tariffs on branded drugs in April, which were met with concern about increased drug costs […]